# GHK-Cu FAQ — Common Questions About the Copper Tripeptide

> Frequently asked questions about GHK-Cu: what it is, how it works, FDA and WADA status, half-life, hair growth, the difference between GHK and GHK-Cu, and what Copper Tripeptide-1 means on a label.

## Q&A

**What is GHK-Cu?**

GHK-Cu is the glycyl-L-histidyl-L-lysine copper(II) complex — a three-amino-acid peptide bound to a single copper ion. It was first isolated from human plasma albumin by Loren Pickart in 1973 [1]. The peptide is endogenous: human plasma carries roughly 200 nanograms per millilitre at age twenty, declining to around 80 nanograms per millilitre by sixty [1]. Total molecular weight is 340.39 daltons, small enough to penetrate skin in suitable carriers.

**How does GHK-Cu work?**

It acts as a master modulator of gene expression. At one to ten nanomolar concentrations in cultured human fibroblasts, it shifts the cell into a tissue-repair posture: upregulating collagen, elastin, and proteoglycan synthesis; modulating matrix metalloproteinases and their inhibitors; suppressing NF-kB-driven inflammation; and activating SIRT1 [1][3][17]. A 2018 transcriptomic review estimated effects on roughly 31 percent of protein-coding genes [1].

**What does the research say about GHK-Cu and skin?**

The topical clinical literature is the most developed part of the human-evidence base. Twelve-week topical GHK-Cu cream studies have shown thickening of the epidermis and dermis, increased keratinocyte proliferation, and collagen deposition in 70 percent of subjects in head-to-head comparison with vitamin C and retinoic acid [6]. A nanolipid-carrier formulation reduced 3D wrinkle volume by 31.6 percent versus comparator after 8 weeks [7]. A 2024 post-laser study reported 25 percent faster re-epithelialization with 0.05 percent topical gel [13].

**Does GHK-Cu actually help hair growth?**

The research signal is real, modest, and primarily topical. Pyo 2007 showed up to 50 percent increases in follicular bulb size in ex vivo cultured human hair follicles [15]. A 2016 6-month topical trial in 45 men reported 52 to 72 additional hairs per defined scalp area with no adverse events [18]. A 2023 mouse study reported faster anagen induction with microemulsion GHK-Cu versus minoxidil [15]. The proposed mechanism is Wnt/beta-catenin activation and VEGF/HGF upregulation in dermal papilla cells [15]. These are not large randomized trials, and effects on humans outside topical cosmetic contexts remain unproven.

**Is GHK-Cu FDA approved?**

Not as a drug for any human indication. Topical Copper Tripeptide-1 is regulated as a cosmetic ingredient and is widely permitted. Injectable GHK-Cu has historically existed only as a compounded preparation; in April 2026 the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations to the 503A bulks list were withdrawn, and the agency has indicated it will consult the Pharmacy Compounding Advisory Committee about future status [14].

**Is GHK-Cu on the WADA prohibited list?**

Not currently. GHK-Cu does not appear on the World Anti-Doping Agency Prohibited List as of the most recent update. This is notable because several other peptides researched in this portfolio (BPC-157, for example) are explicitly listed under WADA S0. Athletes should still confirm against the current WADA list directly before any use, since the prohibited list updates annually.

**What is GHK-Cu's half-life?**

Free GHK has a plasma half-life on the order of minutes; the copper complex is somewhat more stable [1]. The most-cited pharmacokinetic statement in the literature is the comparison of plasma levels by age (200 ng/mL at 20 vs ~80 ng/mL at 60), which describes steady-state endogenous concentrations rather than a clean elimination half-life [1]. Skin retention after topical application is on the order of hours to days depending on vehicle.

**What concentrations are used in GHK-Cu research?**

Cell culture studies cluster at 1 to 100 nanomolar with effects often peaking at 10 nanomolar [1]. Topical cosmetic formulations use 0.05 percent to 2 percent w/w [6][7][13]. Rodent oral colitis studies have used 20 mg/kg by gavage [3]. Rodent intraperitoneal behavioral studies have used 0.5 micrograms/kg [8]. The four orders of magnitude between these systemic-dose studies underscores that very different exposure regimes target very different physiology.

**Is GHK-Cu safe?**

In the topical cosmetic context the safety record is long — multiple controlled topical studies report no significant adverse events at standard formulation strengths [6][7][18]. In animal systemic studies at the doses tested, no acute toxicity is reported in the literature reviewed for this archive. Human systemic safety has not been characterized in large randomized trials, and copper itself can be pro-oxidant in excess — which the complex form mitigates in vitro but does not eliminate as a formulation consideration.

**What is the difference between GHK and GHK-Cu?**

GHK is the bare tripeptide without bound copper. GHK-Cu is the same peptide chelated to a copper(II) ion. Some published studies describe effects of 'GHK' that are presumed to be functionally equivalent to the copper complex because at biological pH and in the presence of available copper the peptide would coordinate copper anyway [1]. The distinction matters most for formulation chemistry and for studies done in copper-depleted conditions.

**Does GHK-Cu work systemically or only topically?**

The strongest human evidence is topical. Systemic effects have been demonstrated in rodents — particularly the 2025 Mao colitis study using 20 mg/kg oral gavage [3] — but no large human trial of systemic GHK-Cu for any indication has been published. The 2012 Campbell COPD lung-fibroblast paper demonstrates that GHK can reverse a disease-associated gene-expression signature in human cells ex vivo, but did not progress to a human respiratory trial [2].

**What is Copper Tripeptide-1?**

Copper Tripeptide-1 is the International Nomenclature of Cosmetic Ingredients (INCI) name for GHK-Cu. If a cosmetic product label lists Copper Tripeptide-1 among its ingredients, that is GHK-Cu. The INCI name is the standardized form used in cosmetic regulation globally.

**Is GHK-Cu the same as a copper amino acid?**

No. The chelation chemistry of GHK-Cu — three specific amino acids in a specific sequence binding copper through a defined coordination geometry — is structurally distinct from generic copper salts or copper bisglycinate. The biological activity profile depends on the specific tripeptide sequence; substituting other amino acids changes the effects substantially.

**Does this site sell GHK-Cu?**

No. This site does not sell any product, is not affiliated with any vendor, and is not a clinic. It is a reading-room archive of the published research literature.

## References cited on this page

[1] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi: 10.3390/ijms19071987

[2] Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012;4(8):67. doi: 10.1186/gm367

[3] Mao S, Huang J, Li J, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Frontiers in Pharmacology. 2025;16:1551843. doi: 10.3389/fphar.2025.1551843

[6] Leyden JJ, Stephens T, Finkey MB, et al. Use of a copper-binding peptide in skin cosmetics (clinical evaluation of GHK-Cu cream over 12 weeks, n=67). Reported in Pickart & Margolina 2018 review. doi: 10.3390/ijms19071987

[7] Badenhorst T, Svirskis D, Wu Z. An anti-aging dermatologic formulation containing the copper peptide tripeptide-1 (GHK-Cu). Journal of Aging Science. 2016;4:166. doi: 10.4172/2329-8847.1000166

[8] Bobyntsev II, Chernysheva OI, Dolgintsev ME, Smakhtin MY, Belykh AE. Influence of Gly-His-Lys peptide on anxiety-related behavior in rats. Bulletin of Experimental Biology and Medicine. 2015;158(6):737-739. doi: 10.1007/s10517-015-2847-3

[13] Topical copper-peptide formulations in post-procedural skin recovery: 2024 multicenter clinical evaluation, summarized in Adnan 2025 review. doi: 10.7150/ijms.118118

[14] U.S. FDA. Confirmed removal of injectable GHK-Cu from Category 2 (April 2026); withdrawn 503A bulks list nominations; Pharmacy Compounding Advisory Committee consultation pending.

[15] Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839. doi: 10.1007/BF02980242

[17] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi: 10.1155/2015/648108

[18] Tricho-test clinical evaluation of a topical GHK peptide complex (45 men, 6 months), reported in Pickart & Margolina 2018 review. doi: 10.3390/ijms19071987

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.